Trinity Biotech PLC (TRIB)
1.37
-0.11
(-7.43%)
USD |
NASDAQ |
Nov 15, 16:00
1.37
0.00 (0.00%)
After-Hours: 20:00
Trinity Biotech Research and Development Expense (TTM): 4.366M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 4.366M |
| March 31, 2024 | 4.608M |
| December 31, 2023 | 4.379M |
| September 30, 2023 | 4.428M |
| June 30, 2023 | 4.282M |
| March 31, 2023 | 4.033M |
| December 31, 2022 | 4.138M |
| September 30, 2022 | 3.913M |
| June 30, 2022 | 3.953M |
| March 31, 2022 | 4.025M |
| December 31, 2021 | 4.497M |
| September 30, 2021 | 4.84M |
| June 30, 2021 | 5.042M |
| March 31, 2021 | 5.139M |
| December 31, 2020 | 5.08M |
| September 30, 2020 | 5.127M |
| June 30, 2020 | 5.095M |
| March 31, 2020 | 5.391M |
| December 31, 2019 | 5.324M |
| September 30, 2019 | 5.379M |
| June 30, 2019 | 5.438M |
| March 31, 2019 | 5.408M |
| December 31, 2018 | 5.369M |
| September 30, 2018 | 5.521M |
| June 30, 2018 | 5.698M |
| Date | Value |
|---|---|
| March 31, 2018 | 5.601M |
| December 31, 2017 | 5.657M |
| September 30, 2017 | 5.449M |
| June 30, 2017 | 5.276M |
| March 31, 2017 | 5.221M |
| December 31, 2016 | 5.04M |
| September 30, 2016 | 5.218M |
| June 30, 2016 | 5.215M |
| March 31, 2016 | 5.217M |
| December 31, 2015 | 5.068M |
| September 30, 2015 | 4.522M |
| June 30, 2015 | 4.367M |
| March 31, 2015 | 4.253M |
| December 31, 2014 | 4.292M |
| September 30, 2014 | 4.366M |
| June 30, 2014 | 4.104M |
| March 31, 2014 | 3.873M |
| December 31, 2013 | 3.691M |
| September 30, 2013 | 3.42M |
| June 30, 2013 | 3.311M |
| March 31, 2013 | 3.14M |
| December 31, 2012 | 3.13M |
| September 30, 2012 | 3.227M |
| June 30, 2012 | 3.317M |
| March 31, 2012 | 3.364M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
3.913M
Minimum
Sep 2022
5.391M
Maximum
Mar 2020
4.614M
Average
4.497M
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Amarin Corp PLC | 20.68M |
| DBV Technologies SA | 83.21M |
| Ascendis Pharma AS | 385.87M |
| Cellectis SA | 94.63M |
| Adaptimmune Therapeutics PLC | 143.17M |